Bristol Myers Squibb said its Phase 2 QUINTESSENTIAL trial of arlo-cel met its primary endpoint in quadruple-class-exposed adults with relapsed or refractory myeloma, reporting a statistically significant and clinically meaningful overall response rate.
Patients had received at least three prior lines of therapy, and the trial also showed strong complete-response rates. The article describes arlo-cel’s safety profile as consistent with existing CAR T and GPRC5D-targeting therapies.
In Q2 2026, BMS revenue rose 6% to $13.0 billion, with Growth Portfolio revenue up 15% to $7.6 billion, while its Legacy Portfolio fell 4% to $5.4 billion amid generic competition. The company raised full-year revenue guidance to $49.0–$50.0 billion and non-GAAP EPS to $6.75–$7.00. Q2 R&D spending rose 15% to $3.0 billion, and BMS projects $16.5 billion in full-year operating expenses. The article identifies regulatory, manufacturing and adoption risks for arlo-cel as potential obstacles to replacing legacy revenue.
